Introduction {#S1}
============

Hepatitis B virus (HBV) infection is a major public health problem worldwide and individuals with chronic HBV (CHB) infection are at high-risk for the development of cirrhosis and hepatocellular carcinoma (HCC) ([@B17]; [@B21]; [@B35]). CHB is associated with ineffective antiviral immune responses ([@B3]; [@B14]), and accumulating evidence supports a relationship between CHB infection and impaired natural killer (NK) cell cytotoxicity and cytokine secretion ([@B22]; [@B44]). Despite this association, the mechanisms involved in NK cell dysfunction in CHB patients are yet to be clarified.

NK cells are the predominant lymphocyte subpopulation in the liver, constituting ∼31% of intrahepatic lymphocytes ([@B29]; [@B26]). NK cell activity is regulated by the combination of activating and inhibitory receptors they express ([@B16]; [@B44]; [@B5]). The chronic viral infection is associated with increased expression of inhibitory receptors on NK cells, which correlates with a poor decline in viral titers after therapy ([@B7]; [@B30]). Recently, NKG2A has been reported as a marker of NK exhaustion in the hepatitis C virus infection and it contributes to viral persistence ([@B43]). During HBV infection, the expression of NKG2A on NK cells is elevated in patients with active CHB, and blocking NKG2A signaling increases NK cell cytotoxicity *in vitro* ([@B12]). Furthermore, high levels of NKG2A expression on NK cells leads to NK cell exhaustion and is associated with poor prognosis for patients with HCC ([@B32]). Anti-NKG2A treatment has been suggested to enhance NK cell activity in cancer vaccinations ([@B9]).

Increased regulatory T cells (Tregs) and interleukin 10 (IL-10) levels in the circulation are associated with weak T cell responses in patients with CHB ([@B24]). Tregs can inhibit NK and CD8^+^ T cell antiviral capacity through their secretion of IL-10 ([@B37]). Furthermore, high levels of IL-10 in patients with CHB inhibit IFN-γ production in NK cells ([@B28]), and intrahepatic IL-10 contributes to the hyporesponsive state of NKG2A^+^Ly49^--^ NK cells in the liver ([@B11]). Li et al. also found that hepatic Tregs contribute to NKG2A expression on murine NK cells, suggesting that reagents designed to block NKG2A signaling have considerable potential for application in the treatment of CHB infection ([@B12]). Moreover, Hepatitis B e antigen (HBeAg, a marker of viral replication) has an important role in viral persistence, and is associated with dysfunctional T cell responses in patients with CHB infection ([@B34]; [@B38]), however, it is not clear whether viral factors are involved in the dysfunction of NKG2A^+^ NK cells in patients with CHB.

In this study, we found that increased percentages of NKG2A^+^ NK cells in peripheral blood correlated with HBV-DNA titers and that blocking NKG2A could restore the function of NK cells isolated from patients with CHB *in vitro*. We also observed a positive correlation between NKG2A^+^ NK cells and IL-10^+^ Tregs in patients with CHB. Moreover, exposure of peripheral blood mononuclear cells (PBMCs) or purified NK cells isolated from healthy controls to CHB sera resulted in impaired NK cell function. Meanwhile, HBeAg-positive patients had higher frequencies of NKG2A^+^ NK cells and Tregs than those who were HBeAg-negative. Our data demonstrate that HBeAg can induce IL-10 secretion in Tregs and that blocking IL-10 enhances NK cell function. Overall, our findings delineate a possible mechanism underlying the dysfunction of NKG2A^+^ NK cells in HBeAg-positive CHB patients and suggest that the HBeAg-IL-10-NKG2A^+^ NK cell axis is a potential therapeutic target in CHB patients.

Materials and Methods {#S2}
=====================

Patients and Healthy Controls {#S2.SS1}
-----------------------------

The results reported in this study were generated from 69 patients with active CHB who had not received antiviral therapy, and 37 age- and sex-matched healthy controls (HCs). In addition, 15 patients with CHB post-therapy were recruited, and this group of patients were treated with entecavir (0.5 mg per day) for 6 months. All patients with CHB were characterized by serum alanine transferase (ALT) levels \> 61 U/L and HBV-DNA levels \> 2000 U/L, and none had overlapping infections with other hepatitis viruses, drug-induced hepatitis, alcoholic hepatitis, tumors, or autoimmune liver diseases. PBMCs were isolated from fresh blood using human peripheral blood lymphocyte isolation fluid (TBD Science, \#LTS1077). The characteristics of enrolled patients with CHB and healthy controls, based on whole blood staining, are summarized in [Table 1](#T1){ref-type="table"}. All patients were diagnosed with CHB and all healthy donors were free from viral hepatitis, autoimmune hepatitis, and tumors. This study was approved by the local ethics committee of The First Affiliated Hospital of Anhui Medical University and the local ethics committee of Chaohu Hospital of Anhui Medical University.

###### 

Clinical characteristics of enrolled subjects.

  Clinical characteristics        CHB-actives           Healthy controls
  ------------------------------- --------------------- ------------------
  Case                            69                    37
  Sex (male)                      50 (62.5%)            22 (59.5%)
  Age, year \[mean ± SEM\]        39.4 ± 1.4            40.7 ± 1.9
  ALT, U/L \[mean ± SEM\]         363.4 ± 56.5          23.2 ± 2.1
  HBV DNA, U/m l \[mean ± SEM\]   (5.27 ± 1.02) E + 7   n.a.
  HBsAg positive                  69/69                 n.a.
  HBeAg positive                  40/69                 n.a.

SEM, standard error of mean; n.a., not applicable.

Purification of Cells {#S2.SS2}
---------------------

NK cells were purified using a human NK cell Isolation Kit (Miltenyi Biotec, 130-092-957) and CD4^+^CD25^+^ Tregs were purified using a human CD4^+^CD25^+^ Regulatory T Cell Isolation Kit (Miltenyi Biotec, 130-091-301). Cell purity was determined by flow cytometry and was \> 90%.

Antibodies and Flow Cytometry {#S2.SS3}
-----------------------------

PBMCs isolated from fresh blood or cultured cells were stained with the following mouse anti-human antibodies: PerCP-Cy5.5-conjugated CD3, BV605 CD3, BV605 CD56, FITC CD56, PE TRAIL, PE NKP30, APC KIR3DL1, APC NKP46, APC CD244, FITC CD4, APC CD25, APC GranzymeB, FITC IFN-γ, PE TNF, and PE IL-10 (BD Biosciences); PE NKG2A, APC NKG2A, and FITC NKG2A (Miltenyi Biotec), and Alexa Flour 660 FoxP3 (eBioscience), and FITC Eomes (Thermo Fisher Scientific). A BD FACSCanto flow cytometer was used to assess stained cells and data were analyzed using Flowjo software VX (TreeStar, United States).

To analyze intracellular IFN-γ and IL-10 secretion, cells were stimulated with medium containing 10% fetal bovine serum (FBS; Gibco) with 50 ng/ml phorbol 12-myristate 13-acetate (Sigma-Aldrich), 50 ng/ml ionomycin (Merck Millipore), and 50 ng/ml monensin (Sigma-Aldrich), concurrently for 4 h. Then, cells were fixed and then permeabilized and stained with FITC mouse anti-human IFN-γ or PE mouse anti-human IL-10.

Cytometric Bead Array {#S2.SS4}
---------------------

Cytokines in serum and culture supernatant samples were analyzed by cytometric bead array (CBA) using a human Th1/Th2 Cytokine Kit II (BD Biosciences, 551809). Samples (50 μl) or standard recombinant protein dilutions were added to a mixture of cytokine beads (IL- 2, IL-4, IL-6, IL-10, TNF, and IFN-γ) and PE-conjugated detection reagent. After 3 h, capture beads were washed using CBA buffer and detected by flow cytometry (BD FACSCalibur), and cytokine concentrations quantified for each sample using recombinant standards and analysis software.

Serological Testing {#S2.SS5}
-------------------

Serum ALT was determined using an automatic biochemical analyzer (Cobas 8000, Roche Diagnostics GmbH, Switzerland). For the measurement of HBsAg and HBeAg, samples were analyzed using commercial enzyme immunoassay kits (Zhongshan Bio-Tech, China). The serum HBV DNA level was quantified using a real-time PCR machine (Roche LightCycler480, Switzerland). The above indicators were measured in The First Affiliated Hospital of Anhui Medical University.

*In vitro* Culture Systems {#S2.SS6}
--------------------------

### PBMC Culture System {#S2.SS6.SSS1}

A total of 2 × 10^5^ PBMCs from patients with CHB were cultured in DMEM (HyClone SH30022.01) supplemented with 10% FBS and IL-2 (100 IU/ml), in the presence of an anti-human NKG2A blocking antibody (CloneZ199, Beckman Coulter, United States) or control IgG (BD Biosciences) at 37°C in 24-well plates. After 7 days, the phenotype and function of NK cells were analyzed by flow cytometry.

PBMCs (2 × 10^5^) isolated from healthy donors were seeded into 24-well plates in DMEM in 20% serum from healthy controls containing 100 IU/ml IL-2, then 500 ng/ml HBeAg (Prospec, HBV272) was added into the wells and cells were cultured for 7 days at 37°C. In the presence of HBeAg, 50 ng/ml anti-human IL-10 neutralizing antibody (Clone25209, R&D, United States) or control IgG (BD Biosciences) was added. The intracellular cytokine in NK cells and the cytokine secreted in the supernatant were measured by flow cytometry.

### Co-culture System {#S2.SS6.SSS2}

NK cells (5 × 10^4^) and autologous CD4^+^CD25^+^ Tregs (5 × 10^4^) purified from healthy donors were cultured with 20% serum from patients with CHB and 50 ng/ml anti-IL-10 neutralizing antibody or control IgG in DMEM containing 100 IU/ml IL-2 for 3 days at 37°C in 96-well plates~.~ The cytokine in the supernatant was measured by flow cytometry after culture.

Purified NK cells (5 × 10^4^) and autologous Tregs (5 × 10^4^) from healthy controls at a 1:1 ratio were co-cultured in DMEM supplemented with 10% FBS and IL-2 (100 IU/ml), with or without 500 ng/ml HBeAg and 50 ng/ml anti-IL-10 or control IgG, in the presence of 50 ng/ml anti-CD3 and 50 ng/ml anti-CD28 (BD Bioscience) for 3 days. NK cells were stained for intracellular expression of IFN-γ and the expression of cytokines in culture supernatant measured by CBA analysis. Cells were cultured in 96-well plates.

Statistical Analysis {#S2.SS7}
--------------------

All data are expressed as the mean ± SEM and were analyzed using GraphPad Prism 5.0 software. The independent samples *t*-test was used to evaluate quantitative variables. Correlation analysis was by Pearson analysis. Significant differences were defined as *P* \< 0.05.

Results {#S3}
=======

Increased Expression of the Inhibitory Receptor, NKG2A, on Circulating NK Cells in Patients With CHB Infection {#S3.SS1}
--------------------------------------------------------------------------------------------------------------

To investigate the NK cell phenotype, we analyzed the expression of activating (NKP30, NKP46, NKG2D, and CD244) and inhibitory (KIR3DL1, NKG2A) receptors on NK cells in the peripheral blood of patients with CHB and healthy controls, respectively. Gating strategies of lymphocytes and NK cells were showed in [Supplementary Figure S1](#DS1){ref-type="supplementary-material"}. Expression of inhibitory receptor, NKG2A, was significantly increased in patients with CHB compared with healthy donors, while there was no difference in the expression of other NK cell receptors, including KIR3DL1, NKP46, NKP30, CD244, and NKG2D ([Figures 1A,B](#F1){ref-type="fig"}) between patients with CHB and healthy controls. Furthermore, both the mean fluorescence intensity and the absolute number of NKG2A^+^ NK cells were higher in peripheral blood from patients with CHB relative to healthy controls ([Figures 1C,D](#F1){ref-type="fig"}), however, there was no significant difference in NKG2A expression on CD8^+^ T cells in patients with CHB compared with healthy controls ([Supplementary Figures S2A,B](#DS1){ref-type="supplementary-material"}). Moreover, in patients with CHB who had received effective antiviral treatment (entecavir, 0.5 mg per day for 6 months), NKG2A levels on NK cells were significantly reduced ([Figures 1E,F](#F1){ref-type="fig"}), and serum levels of HBV-DNA, HBsAg, and HBeAg were also significantly reduced after therapy ([Figures 1G,H](#F1){ref-type="fig"}).

![NKG2A expression is increased on circulating NK cells in patients with CHB. **(A)** NKG2A expression is increased on circulating NK cells in patients with CHB. **(A)** Representative flow cytometry plots showing expression of NKG2A, KIR3DL1, NKP46, NKP30, CD244, NKG2D, and their isotype controls on peripheral NK cells from patients with CHB and healthy controls. **(B)** Comparison of the percentages of receptors in **(A)** expressed on peripheral NK cells in patients with CHB. **(C)** Mean fluorescence intensity (MFI) of NKG2A expression on peripheral NK cells in patients with CHB and healthy controls. **(D)** Absolute numbers of NKG2A + NK cells in peripheral blood samples from patients with CHB and healthy controls. z Representative flow cytometry plots showing NKG2A expression on peripheral NK cells from patients with CHB before and after antiviral therapy. **(F)** The percentage of NKG2A + NK cells in CHB patients before therapy and after therapy. **(G)** The HBV-DNA titers of CHB patients before therapy and after therapy. **(H)** The serum HBsAg and HBeAg levels of CHB patients before therapy and after therapy. Data are representative of more than three independent experiments. Results are presented as the mean ± SEM (*n* ≥ 3 per group) and unpaired/paired two-tailed Student's *t*-tests were conducted; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\*\**p* \< 0.0001; N.S., not significant.](fcell-08-00421-g001){#F1}

NK cells can be divided into two subpopulations, CD56^dim^ and CD56^bright^, and we further investigated NKG2A expression on these two subsets in peripheral blood from patients with CHB. The gating strategies to separate CD56^dim^ and CD56^bright^ NK cells from PBMCs are detailed in [Figure 2A](#F2){ref-type="fig"}. The frequency of NKG2A^+^ cells among the CD56^bright^ NK subpopulation did not differ significantly between these two groups ([Figures 2B,C](#F2){ref-type="fig"}), while the. percentage of NKG2A^+^ cells among the CD56^dim^ NK subpopulation in patients with CHB was significantly higher than that in healthy controls ([Figures 2D,E](#F2){ref-type="fig"}). Furthermore, serum HBV-DNA was found to positively correlate with the percentage of NKG2A^+^CD56^dim^ NK cells in CHB patients (*r* = 0.45, *p* = 0.0001, [Figure 2F](#F2){ref-type="fig"}). In addition, serum levels of HBsAg and HBeAg were found to be positively associated with the percentage of NKG2A^+^CD56^dim^ NK cells (*r* = 0.50, *p* = 0.0003; *r* = 0.49, *p* = 0.03, [Figures 2G,H](#F2){ref-type="fig"}), while there was no significant correlation between NKG2A^+^CD56^dim^ NK cells and the level of transaminases in patients with CHB ([Supplementary Figures S3A,B](#DS1){ref-type="supplementary-material"}).

![Upregulation of NKG2A on CD56^dim^ NK cells and its positive correlation with HBV DNA levels. **(A)** Sequential strategy for gating CD56^dim^ and CD56^bright^ NK cells from lymphocytes with monitoring via flow cytometry. **(B,C)** Representative data plots show NKG2A expression on CD56^dim^ and CD56^bright^ NK cells in healthy controls and patients with CHB. **(D)** NKG2A^+^CD56^bright^ NK cells and **(E)** NKG2A^+^CD56^dim^ NK cells were detected in peripheral blood samples from patients with CHB and healthy controls. **(F)** Correlation between the percentage of NKG2A^+^CD56^dim^ NK cells and serum HBV-DNA levels in patients with CHB. **(G)** Correlation between the percentage of NKG2A^+^CD56^dim^ NK cells and serum HBsAg levels in patients with CHB. **(H)** Correlation between the percentage of NKG2A^+^CD56^dim^ NK cells and serum HBeAg levels in patients with CHB. Data are representative of more than three independent experiments. Results are presented as the mean ± SEM (*n* ≥ 3 per group) and unpaired two-tailed Student's *t-*tests or Spearman's correlation coefficients were used for analyses; \*\*\*\**p* \< 0.0001; N.S., not significant.](fcell-08-00421-g002){#F2}

TNF-related apoptosis-inducing ligand (TRAIL) is expressed by NK cell and it contributes to the elimination of HBV-specific CD8^+^ T cells in CHB ([@B27]). We found that expression of TRAIL was upregulated on NK cells in patients with CHB, however, the frequency of TRAIL^+^ NK cells did not significantly correlate with HBV-DNA in patients with CHB infection ([Supplementary Figures S4A--C](#DS1){ref-type="supplementary-material"}). These results indicate that chronic HBV infection induces an increased expression of NKG2A on CD56^dim^ NK cells, and that upregulation of NKG2A may be linked with the disease progression in CHB.

Blocking NKG2A Restores the Ability of NK Cells From Patients With CHB to Produce Cytokines {#S3.SS2}
-------------------------------------------------------------------------------------------

To evaluate the impact of increased NKG2A expression on NK cells in patients with CHB, we next assessed the function of NK cells from these patients. Gating strategies of lymphocytes, NK cells and CD56^dim^ NK cells were showed in [Supplementary Figure S5](#DS1){ref-type="supplementary-material"}. As shown in [Figure 3A](#F3){ref-type="fig"}, the percentage and absolute numbers of IFN-γ^+^CD56^dim^ NK cells were lower in patients with CHB than those in healthy controls ([Figures 3B,C](#F3){ref-type="fig"}). Moreover, the frequency and absolute number of TNF^+^CD56^dim^ NK cells were also significantly decreased in patients with CHB relative to controls ([Figures 3D,E](#F3){ref-type="fig"}). These data demonstrate that cytokine production is impaired in NK cells from patients with CHB relative to healthy controls.

![Cytokine production by CD56^dim^ NK cells is restored after blockade of NKG2A signaling in patients with CHB**. (A)** Representative flow cytometry plots showing IFN- γ and TNF expression in NK cells from patients with CHB and healthy controls. **(B)** Analysis of IFN- γ ^+^CD56^dim^ NK cells in patients with CHB and healthy controls. **(C)** Comparison of absolute numbers of IFN - γ ^+^ CD56^dim^ NK cells in patients with CHB and healthy controls. **(D)** Analysis of TNF^+^CD56^dim^ NK cells in patients with CHB and healthy controls. **(E)** The absolute number of TNF^+^CD56^dim^ NK cells in patients with CHB and healthy controls. **(F--M)** NK cells isolated from patients with CHB were cultured in DMEM supplemented with 10% FBS and 100 IU/ml IL-2, with anti-human NKG2A antibody or control IgG. After 3 days, the phenotype and function of NK cells were analyzed by flow cytometry. **(F)** Representative plots of NKG2A and CD226 expressed in CD56^dim^ NK cells after NK cells were cultured with anti-human NKG2A antibody or control IgG. **(G)** Expression of CD226 on total NK cells, CD56^bright^ and CD56^dim^ NK cells after isolated CHB NK cells were cultured with anti-human NKG2A antibody or control IgG. **(H)** Representative plots of IFN- γ expressed in CD56^dim^ NK cells after NK cells were cultured with anti-human NKG2A antibody or control IgG. **(I)** Expression of IFN- γ on total NK cells, CD56^bright^ and CD56^dim^ NK cells after isolated CHB NK cells were cultured with anti-human NKG2A antibody or control IgG. **(J)** Representative plots of TNF expressed in CD56^dim^ NK cells after NK cells were cultured with anti-human NKG2A antibody or control IgG. **(K)** Expression of TNF on total NK cells, CD56bright and CD56^dim^ NK cells after isolated CHB NK cells were cultured with anti-human NKG2A antibody or control IgG. **(L)** Representative plots of Eomes expressed in CD56^dim^ NK cells after NK cells were cultured with anti-human NKG2A antibody or control IgG. **(M)** Expression of Eomes on total NK cells, CD56^brigh^t and CD56^dim^ NK cells after isolated CHB NK cells were cultured with anti-human NKG2A antibody or control IgG. Results are presented as the mean ± SEM (*n* ≥ 3 per group) and unpaired/paired two-tailed Student's *t*-tests were conducted; \**p* \< 0.05, \*\**p* \< 0.01. N.S., not significant.](fcell-08-00421-g003){#F3}

Next, to investigate the role of NKG2A in NK cell function, we purified NK cells from patients with CHB and incubated them with anti-human NKG2A blocking antibody *in vitro* ([Supplementary Figure S6B](#DS1){ref-type="supplementary-material"}). Gating information of CD56^dim^ NK cells was showed in [Supplementary Figure S6A](#DS1){ref-type="supplementary-material"}. Our results showed that blocking NKG2A significantly enhanced expression of the activating receptor, CD226, on CD56^dim^ NK cells isolated from patients with active CHB ([Figures 3F,G](#F3){ref-type="fig"}), and significantly increased the expression of IFN-γ ([Figures 3H,I](#F3){ref-type="fig"}) as well as TNF in CD56^dim^ NK cells ([Figures 3J,K](#F3){ref-type="fig"}). Meanwhile, the frequency of Eomes^+^CD56^dim^ NK cells was also significantly enhanced when NKG2A was blocked ([Figures 3L,M](#F3){ref-type="fig"}). While the expression of CD226, IFN-γ, TNF and Eomes on NK cells were significantly increased in NKG2A blockade group compared with control, but there was no significant difference in the expression of these four markers on CD56^bright^ NK cells between these two groups ([Supplementary Figures S6C--F](#DS1){ref-type="supplementary-material"}). In addition, the expression of TRAIL and Granzyme-B did not change significantly in this assay (*P* \> 0.05, [Supplementary Figures S6G,H](#DS1){ref-type="supplementary-material"}). These results suggest that the inhibitory receptor, NKG2A, expressed on NK cells, accounts for the impaired ability of NK cells to produce cytokines in patients with CHB infection, and that blocking NKG2A *in vitro* can restore the function of those NK cells.

IL-10^+^ Tregs Contribute to the Dysfunction of NKG2A^+^ NK Cells in Patients With CHB {#S3.SS3}
--------------------------------------------------------------------------------------

We wondered which factors were responsible for the induction of NKG2A expression on NK cells. First, we examined CD4^+^CD25^+^Foxp3^+^ Tregs in patients with CHB and found that both the proportion and absolute number of Tregs in peripheral blood were significantly higher in patients with CHB than those in healthy controls ([Figures 4A--C](#F4){ref-type="fig"}). Next, we measured cytokine production in Tregs and found that Tregs from CHB patients produced much higher levels than those from healthy controls ([Figures 4D,E](#F4){ref-type="fig"}). Further, we assessed the level of serum IL-10 in healthy controls and CHB patients who had received effective antiviral therapy, and found that serum IL-10 level in treated CHB patients returned to a normal level, which was significantly lower than that in patients with CHB who had not received effective therapy ([Figure 4F](#F4){ref-type="fig"}).

![Circulating Tregs and secreted IL-10 in patients with CHB infection. **(A)** Representative flow cytometry plots showing CD4^+^CD25^+^FOXP3^+^ Tregs in peripheral blood samples from patients with CHB and healthy controls. **(B)** Data from **(A)** were compiled and analyzed for significance using the *t*-test. **(C)** Comparison of the absolutely numbers of CD4^+^CD25^+^FOXP3^+^ Tregs in peripheral blood samples from patients with CHB and healthy controls. **(D)** Representative flow cytometry plots of IL-10^+^ Tregs in peripheral blood samples from patients with CHB and healthy controls. **(E)** Data from **(D)** were compiled and analyzed for significance using the *t*-test. **(F)** Comparison of serum IL-10 levels detected using a CBA kit in healthy controls, and patients with CHB patients before and after antiviral treatment. Data are representative of more than three independent experiments. Results are presented as the mean ± SEM (*n* ≥ 3 per group) and unpaired two-tailed Student's *t*-tests and one-way ANOVA were conducted; \**p* \< 0.05, \*\*\*\**p* \< 0.0001. N.S., not significant.](fcell-08-00421-g004){#F4}

Interestingly, we detected a positive correlation between the percentage of Tregs and that of NKG2A^+^CD56^dim^ NK cells ([Figure 5A](#F5){ref-type="fig"}). And both the percentage of IL-10^+^ Tregs and serum IL-10 level positively correlated with the percentage of NKG2A^+^CD56^dim^ NK cells ([Figures 5B,C](#F5){ref-type="fig"}). To evaluate the effects of IL-10 on NKG2A expression, PBMCs were isolated from healthy donors and stimulated with 20% sera from CHB patients. We observed that the percentages of NKG2A^+^ and CD94^+^ NK cells were significantly increased by stimulation with CHB sera ([Figures 5D,E](#F5){ref-type="fig"}). Interestingly, the percentage of NKG2A^+^ NK cells was significantly reduced in PBMCs stimulated with CHB sera in the presence of anti-IL-10, relative to those stimulated with CHB sera only ([Figure 5F](#F5){ref-type="fig"}). Furthermore, the percentage of NKG2A^+^ NK cells was lower accompanied by a higher frequency of IFN-γ ^+^ and TNF^+^ NK cells in the IL-10 blockade group when compared to that in the control group ([Figures 5G,H](#F5){ref-type="fig"}). Accordingly, when NK cells and Tregs purified from healthy controls were stimulated with anti-CD3 and anti-CD28, and cultured with anti-human IL-10 neutralizing antibody or control IgG in the presence of CHB sera, we found that the concentrations of IFN-γ and TNF in the culture supernatant were significantly increased after IL-10 blockade ([Figures 5I,J](#F5){ref-type="fig"}). These findings suggest that Treg-derived IL-10 is involved in induction of NKG2A^+^ NK cell and NK cell dysfunction.

![Treg-derived IL-10 impairs NK cell function in patients with CHB. **(A)** Correlation between the percentage of NKG2A^+^CD56^dim^ NK cells and Tregs in patients with CHB determined by flow cytometry. **(B)** Correlation between the percentage of NKG2A^+^CD56^dim^ NK cells and serum IL-10 levels in serum samples from patients with CHB patients. **(C)** Correlation between the percentage of NKG2A^+^CD56^dim^ NK cells and IL-10^+^ Tregs in peripheral blood samples from patients with CHB. **(D,E)** PBMCs from healthy donors were cultured with 100 IU/ml IL-2 in the presence of 20% CHB or healthy control serum for 7 days. After 7 days of culture in the presence of 20% CHB or healthy control serum, expression of NKG2A and CD94 was monitored on NK cells by flow cytometry. **(F--H)** PBMCs from healthy donors were cultured with 20% CHB and 100 IU/ml IL-2 in the presence of 50 ng/ml anti-human IL-10 neutralizing antibody or control IgG. After 7 days, the percentages of NKG2A^+^ NK cells, IFN- γ^+^ NK cells and TNF^+^ NK cells were detected after treatment of PBMCs with CHB serum and anti-IL-10 or control IgG *in vitro*. **(I,J)** NK cells (5 × 104) and Tregs (5 × 104) were purified from healthy donors and co-cultured in the presence of 20% CHB patient serum and 100 IU/ml IL-2, supplemented with anti-CD3 and-CD28 mAb, with 50 ng/ml anti-human IL-10 neutralizing antibody for 3 days. **(I)** The concentration of IFN-γ in the supernatant was measured using a CBA kit. **(J)** The concentration of TNF in the supernatant was measured using a CBA kit. Data are representative of more than three independent experiments. Results are presented as the mean ± SEM (*n* ≥ 3 per group) and paired two-tailed Student's *t*-tests or Spearman's correlation coefficients were conducted; \**p* \< 0.05; \*\**p* \< 0.01.](fcell-08-00421-g005){#F5}

HBeAg Induces NKG2A+ NK Cell Dysfunction Mediated by Treg-Derived IL-10 {#S3.SS4}
-----------------------------------------------------------------------

HBeAg has been suggested to play an important role in maintaining HBV persistence in patients with CHB. We next compared serum ALT and HBV-DNA between HBeAg-positive and -negative patients, and found that ALT and HBV-DNA levels were higher in HBeAg-positive patients than those that are HBeAg-negative ([Figures 6A,B](#F6){ref-type="fig"}). Specifically, we observed that HBeAg-positive patients had significantly increased serum level of IL-10, as well as increased percentages of total Tregs, IL-10^+^ Tregs and NKG2A^+^ NK cells, respectively ([Figures 6C--F](#F6){ref-type="fig"}). Together, these results suggest that HBeAg is associated with Treg-derived IL-10 production and NKG2A expression on NK cells in CHB patients.

![HBeAg-induced IL-10 suppresses NK cell activation *in vitro*. **(A)** Serum ALT levels, **(B)** serum HBV DNA copy numbers, **(C)** serum IL-10 levels, **(D)** CD56^+^NKG2A^+^ NK expression, **(E)** percentages of Tregs, and **(F)** percentages of IL-10^+^ Tregs were compared in HBeAg-positive and -negative patients with CHB. **(G--I)** For vitro experiments, PBMCs (2 × 10^5^) isolated from healthy donors were cultured with or without 500 ng/ml HBeAg and 50 ng/ml anti-human IL-10 neutralizing antibody or control IgG in the presence of 100 IU/ml IL-2 for 7 days and the concentrations of cytokines in culture supernatant measured using a CBA kit. **(G)** IL-10 levels in supernatant after culture of PBMCs from healthy donors with or without HBeAg. **(H,I)** IFN-γ and TNF levels in supernatant after culture of PBMCs with HBeAg, in the presence of anti-IL-10 or control IgG. **(J--L)** In the co-culture system, 5 × 10^4^ NK cells and 5 × 10^4^ Tregs were purified from healthy donors and then co-cultured in the presence of 10% FBS, anti-CD3, and -CD28 mAb, with or without 500 ng/ml HBeAg and 50 ng/ml anti-IL-10 or control IgG in the presence of 100 IU/ml IL-2 for 3 days, then the concentration of cytokines in supernatant were measured using a CBA kit. **(J)** IL-10 in culture supernatants after co-culture of NK cells and Tregs with or without HBeAg for 3 days. **(K,L)** IFN-γ and TNF levels were detected in culture supernatant after co-culture of NK cells and Tregs with HBeAg in the presence of anti-IL-10 or control IgG. Data are representative of more than three independent experiments. Results are presented as the mean ± SEM (*n* ≥ 3 per group) and unpaired/paired two-tailed Student's *t-*tests were conducted; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fcell-08-00421-g006){#F6}

To delineate the effect of HBeAg on NKG2A^+^ NK cell dysfunction in patients with CHB, PBMCs were isolated from healthy controls and stimulated with HBeAg *in vitro*. We found that HBeAg induced human PBMCs to produce significantly more IL-10 upon stimulation with PMA, ionomycin, and monensin *in vitro* ([Figure 6G](#F6){ref-type="fig"}). Moreover, levels of TNF and IFN-γ were decreased in PBMCs stimulated with HBeAg, while anti-IL-10 treatment increased the levels of these cytokines in the culture supernatant ([Figures 6H,I](#F6){ref-type="fig"}). To test the direct effect of HBeAg on regulating NK cells, we added HBeAg directly to NK cells alone, but found that the frequency of NKG2A^+^ NK cells did not alter significantly ([Supplementary Figure S7](#DS1){ref-type="supplementary-material"}). To directly investigate the possible role of HBeAg in regulating Treg and NK cells, these cells were purified from healthy controls and co-cultured *in vitro*. Addition of HBeAg to the culture system in the presence of anti-CD3 and anti-CD28 led to increased amounts of IL-10 in the supernatant ([Figure 6J](#F6){ref-type="fig"}), accompanied by reduced levels of TNF and IFN-γ ([Figures 6K,L](#F6){ref-type="fig"}); the defective production of these two cytokines was restored by addition of anti-IL-10 ([Figures 6K,L](#F6){ref-type="fig"}). Together, these findings indicate that HBeAg promotes IL-10 production by Tregs, thereby inducing NKG2A expression on NK cells and contributing to the impaired cytokine-produced ability of NK cells.

Discussion {#S4}
==========

CHB infection-induced immune tolerance is the biggest obstacle to the elimination of HBV in the host. As the vital effector lymphocytes of innate immune system, NK cells have an important role in defending against viruses and tumors, via rapid cytotoxic activity and cytokine production. In this study, we demonstrate that the percentage of NKG2A^+^ NK cells increased in patients with CHB. We found that NKG2A^+^CD56^dim^ NK cells correlated with HBV infection and NKG2A blockade could restore the function of NK cells *in vitro*. Furthermore, IL-10^+^ Treg cells increased in patients with CHB and the frequency of NKG2A^+^ NK cells was positively associated with Treg-derived IL-10, which is likely to contribute to the induction of NKG2A^+^ NK cell dysfunction in CHB patients. Moreover, we found that the frequency of NKG2A^+^ NK cell and level of Treg-derived IL-10 were elevated in HBeAg-positive patients relative to HBeAg-negative patients and that HBeAg promoted IL-10 production by Tregs, which further contributed to increased NKG2A expression on NK cells resulting in NK cell dysfunction ([Figure 7](#F7){ref-type="fig"}).

![HBeAg induces NKG2A^+^ NK cell dysfunction via Tregs-derived IL-10. The diagram shows that HBeAg induces NK cell dysfunction with upregulated expression of NKG2A on NK cells and reduced secretion of TNF and IFN- γ, which is mediated by increased amounts of IL-10 secreted from Tregs. On the one hand, blocking NKG2A on NK cells leads to the recovery of NK cell function. On the other hand, the function of NK cells is also restored by addition of anti-IL-10.](fcell-08-00421-g007){#F7}

NK cells are critical for HBV clearance in an HBV-transfected mouse model mimicking acute HBV infection in patients ([@B45]). The expression pattern of various receptors on NK cells is abnormal, leading to their dysfunction during CHB infection ([@B31]; [@B25]). Down-regulation of activating receptors and up-regulation of inhibitory receptors on NK cells are associated with increased HBV viral load ([@B36]). NKG2A is also important for the maintenance of persistent hepatitis C virus infection ([@B8]). In patients with HCC, NKG2A, a checkpoint candidate, is expressed on NK cells and mediates NK cell dysfunction in intratumor tissues ([@B32]). [@B12] found that NKG2A expression is higher in patients with CHB and that, in a mouse model established by transfection of HBV plasmid, blocking NKG2A signaling promotes viral clearance. These data are consistent with our finding that up-regulation of NKG2A on CD56^dim^ NK is positively associated with the serum levels of HBV-DNA, HBsAg, and HBeAg in patients with CHB ([Figure 2](#F2){ref-type="fig"}). We also demonstrated that NKG2A blockade restores the function of CD56^dim^ NK cells; specifically, this blockade enhances the IFN-γ and TNF production, and induces the expression of CD226 and Eomes in CD56^dim^ NK cells *in vitro* ([Figure 3](#F3){ref-type="fig"}). Furthermore, NKG2A is expressed on CD8^+^ T cells ([@B23]), however, no significant expression of NKG2A was detected on CD8^+^ T cells in CHB patients in our study ([Supplementary Figure S1](#DS1){ref-type="supplementary-material"}). As NK cell dysfunction is associated with impaired CD8^+^ T cell responses in liver disease ([@B13]; [@B46]), it is possible that the elevated expression of NKG2A on NK cells is linked with dysfunctional CD8^+^ T cells in patients with CHB.

In addition, after 24-week tenofovir treatment, the percentage of NKG2A^+^ NK cells transiently decreased ([@B20]). Similarly, following treatment with PEG-interferon alpha-2a and adefovir for 48 weeks, the cytotoxic function of NK cells was restored and their IFN-γ secretion increased, while the number of NKG2A^+^ NK cells was notably down-regulated ([@B2]). In this study, we found that the frequency of NKG2A^+^ NK cells, serum level of IL-10, and the levels of HBV-DNA, HBeAg, and HBsAg were significantly reduced after antiviral therapy ([Figures 1E--G](#F1){ref-type="fig"}). IL-10 has an important role in sustaining the expression of NKG2A^+^Ly49^--^ on hepatic NK cells ([@B11]). In an HBV-transfected mouse model, Li et al. demonstrated that Treg-derived IL-10 contributes to the upregulation of NKG2A expression on NK cells ([@B12]). In liver diseases (e.g., CHB, cirrhosis and liver cancer), NK cell dysfunction is induced by elevated levels of IL-10 and TGF-β ([@B19]; [@B39]). The production of IL-10 is significantly enhanced by increased HBV titers, and IL-10 may suppress IFN- γ production in NK cells in patients with CHB ([@B15]; [@B28]; [@B33]). Our data show that Tregs increased the percentage of NKG2A cells in the presence of CHB serum supplemented with anti-CD3 and CD28, while secretion of IFN-γ and TNF from NK cells was up-regulated by IL-10 blockade in this co-culture system ([Figure 5](#F5){ref-type="fig"}).

HBeAg positivity is associated with viral replication and immunotolerance in CHB infection ([@B6]). Moreover, CD4^+^CD25^+^ T cells are significantly elevated in HBeAg-positive patients when compared to HBeAg-negative patients, and their number is positively correlated with HBeAg levels ([@B4]). HBeAg evades host immune responses by inhibiting lipopolysaccharide-induced NLRP3 inflammasome activation, which is critical for antiviral defense ([@B42]). Loss of HBeAg is associated with short-term evolution, as it results in loss of HBeAg-mediated tolerance and reduced transmissibility of the HBeAg(-) virion ([@B10]). Furthermore, maternal-derived HBeAg was reported to contribute to the impaired function of hepatic macrophage cells ([@B34]). Consistently, HBeAg-induced expansion of monocytic myeloid-derived suppressor cells leads to impaired CD8^+^ T cell responses in CHB infection ([@B38]). Moreover, the frequency and skewed T-cell receptor beta-chain variable patterns of peripheral Tregs correlate with HBeAg seroconversion ([@B40]), and CD3^+^CD4^+^Foxp3^--^ cells can be induced to convert into CD3^+^CD4^+^Foxp3^+^ Tregs in liver-draining lymph nodes ([@B41]). There are also reports indicating that liver sinusoidal endothelial cells and B cells contribute to Treg induction ([@B1]; [@B18]).

In our study, we demonstrate that HBeAg-positive patients had higher frequencies of NKG2A^+^ NK cells than those who were HBeAg-negative. Tregs and IL-10 derived from these cells were significantly elevated in HBeAg-positive patients. When PBMCs or NK cells and Tregs purified from healthy controls were co-cultured with anti-CD3 and anti-CD28 *in vitro*, the addition of HBeAg led to increased production of IL-10 accompanied by reduced levels of TNF and IFN-γ, while the addition of HBeAg to NK cells alone did not have significant impact on the function of NK cells. Furthermore, the production of TNF and IFN-γ was restored by IL-10 blockade. These results indicate that HBeAg contributes to the up-regulation of IL-10^+^ Tregs, then causing NK cell dysfunction ([Figure 6](#F6){ref-type="fig"}).

In summary, during CHB infection, HBeAg is associated with HBV immune tolerance. We found that HBeAg induces IL-10 production in Tregs, which subsequently upregulates the expression of NKG2A on NK cells, leading to NK cell dysfunction, suggesting that HBeAg accounts for NK cell dysfunction in CHB patients. Together, our findings contribute to the understanding of the mechanisms underlying NK cell dysfunction in CHB patients and indicate that the HBeAg-IL-10-NKG2A^+^ NK cell axis is a potential therapeutic target in these patients.
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